News - Fore Biotherapeutics

Press Release 17.11.2023 FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors Read more

Press Release 10.11.2023 FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting Read more

Press Release 12.10.2023 FORE Biotherapeutics to Present Plixorafenib Nonclinical Data Highlighting Potential Differentiation at the 2023 AACR-NCI-EORTC International Conference Read more

Press Release 23.08.2023 FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition Read more

Press Release 26.05.2023 FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 2023 Read more

Press Release 26.04.2023 FORE Biotherapeutics Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Read more

Press Release 20.03.2023 FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies Read more

Press Release 23.02.2023 FORE BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN GLOBAL PHASE 2 TRIAL EVALUATING FORE8394 IN BRAF-MUTATED SOLID AND BRAIN TUMORS Read more

Press Release 28.09.2022 FORE BIOTHERAPEUTICS ANNOUNCES FAST TRACK DESIGNATION GRANTED BY FDA TO FORE8394 FOR THE TREATMENT OF CANCERS HARBORING BRAF CLASS 1 AND CLASS 2 ALTERATIONS Read more

Press Release 12.09.2022 Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022 Read more